GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All Semaglutide Brands India
Generic SemaglutideType 2 Diabetes + Obesity
Zydus Lifesciences logo

Semaglyn/ Mashema / AltermeGeneric semaglutide for type 2 diabetes + obesity in India 2026

by Zydus Lifesciences · ₹2,200–5,500/month · DCGI approved March 2026

Active ingredient
Semaglutide (GLP-1 receptor agonist)
Indication
Type 2 Diabetes + Obesity
Manufacturer
Zydus Lifesciences Ltd
DCGI status
Approved March 2026
Price (MRP)
₹2,200–5,500/month
Lower range for T2D dosing, higher for obesity-dose maintenance
Format
Reusable multi-dose pen
15 mg / 3 mL cartridge — replace cartridges, not the device
Prescription
Schedule H — required

How Semaglyn compares

Semaglyn is the only reusable-pen semaglutide on the Indian market. Patients keep the same device through dose-titration, replacing only cartridges — a meaningful cost and convenience advantage during the standard 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg/week escalation. Mashema and Alterme are sister brand names for the same product, used for distinct distribution channels.

About Zydus Lifesciences

Zydus Lifesciences holds the largest licensing footprint among Indian semaglutide generics, with co-marketing agreements covering Lupin (Semanext, Livarise) and Torrent (Sembolic, Semalix). Effectively, Zydus is the manufacturing platform for several of the leading Indian generic brands.

Who is Semaglyn for?

Semaglyn is approved in India for both type 2 diabetes and chronic weight management in adults with obesity. Indian guideline eligibility typically requires BMI ≥27.5 (obesity indication) or HbA1c above target on first-line therapy (T2D indication). Patients with BMI ≥25 + comorbidities (PCOS, NAFLD, hypertension, sleep apnea) may also qualify under specialist judgment.

Not sure if you qualify? Take the 5-minute Indian-guideline eligibility check →

Semaglyn for specific conditions

Semaglyn for PCOS →Semaglyn for fatty liver (NAFLD/MASLD) →Semaglyn for hypertension + obesity →Semaglyn for sleep apnea + obesity →

Semaglyn cost in India

MRP for Semaglyn: ₹2,200–5,500/month. Actual pharmacy pricing varies by city, pharmacy, and channel. Online prescription pharmacies typically offer modest discounts off MRP with cold-chain delivery; hospital pharmacy pricing is usually at MRP.

Compare with all India brands: GLP-1 therapy cost in India 2026 →

Compared to other GLP-1 brands in India

Semaglyn is an Indian generic semaglutide. Same active molecule as Ozempic and Wegovy (Novo Nordisk innovator brands), with clinical efficacy that follows the molecule rather than the brand. Other Indian generics include Sundae, Noveltreat, Obeda, Semaglyn, Sembolic, and Samakind — all at similar price points.

All GLP-1 comparisons →All Indian semaglutide brands →Clinical evidence library →GLP-1 blog (India) →

Semaglyn — frequently asked questions

Is Semaglyn available in India? Is it DCGI-approved?+
Yes — Semaglyn is DCGI-approved and currently available across India. The drug received DCGI approval in March 2026 for both type 2 diabetes and obesity, manufactured by Zydus Lifesciences Ltd. It is distributed through licensed retail and online prescription pharmacies and hospital pharmacies across Indian metros and most tier-2 cities. Semaglyn is a Schedule H drug — a doctor's prescription is required. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
What does Semaglyn cost in India in 2026?+
Semaglyn is priced at ₹2,200–5,500/month (Lower range for T2D dosing, higher for obesity-dose maintenance). Actual pharmacy pricing may vary by city and channel. For brand-by-brand price comparisons across all India brands, see our cost guide. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
Do I need a prescription to buy Semaglyn?+
Yes — Semaglyn is a Schedule H drug in India and can only be dispensed against a valid prescription from a registered medical practitioner. Any legitimate online prescription pharmacy will require you to upload your prescription before order fulfillment.
Who is Semaglyn for?+
Semaglyn is approved for both type 2 diabetes and obesity in India. Indian guideline eligibility typically requires BMI ≥27.5 (obesity indication) or HbA1c above target on first-line therapy (T2D indication), often with comorbidities at BMI ≥25. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
How does Semaglyn compare to Ozempic and Wegovy?+
Semaglyn contains the same active molecule (semaglutide) as Ozempic and Wegovy. Clinical efficacy is comparable; the difference is brand, manufacturer support, pen design, and price. Semaglyn (₹2,200–5,500/month) is meaningfully cheaper than Ozempic (₹5,660+/month) or Wegovy (up to ₹16,400/month) — useful for cost-sensitive patients on long-term therapy.
Where can I buy Semaglyn in India?+
Semaglyn is a Schedule H drug — available through licensed retail and online prescription pharmacies and hospital pharmacies across India with a doctor's prescription. Always buy from a licensed pharmacy to avoid counterfeit products; never use sources that dispense without verifying a prescription. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
Official

Manufacturer announcement

Zydus Lifesciences — Semaglutide launch announcement (March 2026)

Additional source

Business Standard — Zydus semaglutide launch

GLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.

Are you eligible for Semaglyn?

Take the free 5-minute triage to check your GLP-1 readiness against Indian clinical guidelines.

Check My Eligibility →

Looking at other brands?

See full price comparison across all 25+ DCGI-approved brands →